ARLINGTON, VA., The world market for diagnostics is estimated at $69.2 billion in 2019 and is expected to grow a little more than 4% annually to reach $85.2 billion by 2024. This is according to an upcoming report by market researcher Kalorama Information, part of Science and Medicine Group. This estimate includes all laboratory and […]
Kalorama Information attended the American Association of Clinical Chemistry in Anaheim this year. We analyzed products and trends, interviewed vendors and experts, and gathered information for our 12 Edition Worldwide Market for In Vitro Diagnostics Tests report, due out this month. Time is of the essence, it is said, and that was the case […]
We have just published our latest report, The World Market for Biomarkers. Biomarkers are biological or biochemical molecules, genetic changes, or other characteristics that can be measured; they indicate or predict a condition, risk, or likely biological response. Biomarkers can be used for a range of diagnostic applications including predicting disease risk, diagnosis, predicting prognosis, […]
We recently published a customer experience survey. This blog highlights discusses the report and highlights the major findings of the report, including important recommendations for the clinical diagnostics industry. For specific vendor performance and user ratings, a purchase of the report is suggested. Clinical laboratory customers have become increasingly sophisticated and typically have multiple suppliers […]
By Emily Hayes, LabPulse.com editor in chief FROM Kalorama’s partner publication Lab Pulse.com Testing for the tau protein in blood could help predict the outlook for the rare and deadly Creutzfeldt-Jakob disease (CJD), a discovery that also has implications for research in Alzheimer’s disease and other neurodegenerative disorders, researchers reported in JAMA Neurology on May 6. Tau is […]
Introducing accurate test results to the place where patient care is occurring is a compelling concept for improved care. And that is reflected in the growing year-over-year revenues for products that are successful at getting that done. POC has not converted in every category, and it’s not for everything. Indeed, lab-based tests remain stalwart in […]
[by Christina Chew] It is increasingly common to test in panels to gain clarity on disease while treatment will be most effective. Numerous multiplex products are on the market, and their effectiveness has been shown in studies, but there are challenges with reimbursement. In this article, we will look at the current status of syndromic […]
The CDC reports a late peak and possible second wave to what was previously thought to be a weaker flu season compared to recent years. This is important for IVD makers, as respiratory IVD markets are driven to a great extent by the severity of the flu season. While the total number of cases remains […]
Detection of infectious disease promptly and accurately is important because the burden of infectious disease is high. In the United States, chronic lower respiratory diseases were the third leading cause of death in 2015, behind only heart disease and cancer. The Center for Disease Control and Prevention (CDC) reports that 155,041 people died in the […]
There is IVD sold almost everywhere in the world but revenue growth is not found everywhere. For most of the top IVD companies, adding scores of millions in growth would be helpful to business plans. That’s why growth regions such as Latin America offer promise beyond their market size. The maturation of IVD markets in developed countries (growth […]
